

---

**MEDICINE**


---

УДК 617.583-089.28/29-06

**ANALYSIS OF COMPLICATIONS TOTAL KNEE REPLACEMENT**

© 2015 г. A.V. Alabut, V.D. Sikilinda, S.G. Chesnikov, M.E. Timoshenko, A.A. Skarzhinskii, M.O.Kh. Khammad

*Alabut Anna Vladimirovna – Doctor of Medical Science, Associate Professor, Department of Traumatology and Orthopedics, Head of Traumatology and Orthopedic Department of Hospital, Rostov State Medical University, Nakhichevanskii Lane, 29, Rostov-on-Don, 344022, Russia, e-mail: alabut@mail.ru*

*Sikilinda Vladimir Danilovich – Doctor of Medical Science, Professor, Head of Traumatology and Orthopedic Department, Rostov State Medical University, Nakhichevanskii Lane, 29, Rostov-on-Don, 344022, Russia, e-mail: v.sikilinda@yandex.ru*

*Chesnikov Sergei Gennadievich – Head of Traumatology and Orthopedic Department, Rostov Clinical Hospital, Peshkov St., 34, Rostov-on-Don, 344045, Russia, e-mail: anna-kard@yandex.ru*

*Timoshenko Mikhail Evgen'evich – Doctor, Department of Traumatology and Orthopedics, Rostov Clinical Hospital, Peshkov St., 34, Rostov-on-Don, 344045, Russia.*

*Skarzhinskii Aleksei Aleksandrovich – Doctor, Department of Traumatology and Orthopedics, Rostov Clinical Hospital, Peshkov St., 34, Rostov-on-Don, 344045, Russia.*

*Khammad Mokhammad Omar Khasan – Post-Graduate Student, Department of Traumatology and Orthopedics, Rostov State Medical University, Nakhichevanskii Lane, 29, Rostov-on-Don, 344022, Russia.*

*The article analyzes of complications of total knee arthroplasty. Materials and methods: The results of treatment of 885 patients who underwent total knee arthroplasty in the period from 2003 to 2013. Women was 684 (77,29%), men – 201 (22,71 %). Age range – from 19 to 82 years, mean age – 61,68 years. Results: in the immediate and late postoperative period in 10 patients (1,13 %) were reported complications: 1 (0,11 %) – persistent contracture, 3 (0,34 %) – deep sepsis, 1 (0,11 %) – aseptic loosening, 2 (0,23 %) – persistent arthralgia, 3 (0,34 %) – non-fatal pulmonary embolism. Venous thromboembolic events were recorded in 87 (9,83 %) patients, hemorrhagic complications – in 18 (2,03 %) patients.*

**Keywords:** replacement of the knee joint, complications total knee replacement.

**References**

1. Efimenko N.A., Gitsyuk A.A., Sereda A.P. Antibiotikoprofilaktika v travmatologii i ortopedii [Antibiotic prophylaxis in trauma and orthopedics]. *Infektsii v khirurgii*, 2008, vol. 6, no 2, pp. 9-14.
2. Lentino J.R. Prosthetic Joint Infections: Bane of Orthopedists, Challenge for Infectious Disease Specialists. *Clin. Inf. Dis.*, 2003, vol. 36, pp. 1157-1161.
3. Rumyantsev Yu.I. Luchevaya diagnostika oslozhnenii posle endoprotezirovaniya tazobedrennogo i kolennogo sustavov [Radiological diagnosis of complications after hip and knee joints]. *Radiologiya-praktika*, 2011, n 4, pp. 95-96.
4. Kopenkin S.S. Profilaktika venoznykh tromboembolicheskikh oslozhnenii v ortopedicheskoi khirurgii: novye vozmozhnosti [Prevention of venous thromboembolic complications in orthopedic surgery: new opportunities]. *Vestnik travmatologii i ortopedii im. N.N. Priorova*, 2010, no 1, pp. 35-39.
5. Matziolis G., Perka C., Labs K. Acute arterial occlusion after total knee arthroplasty. *Arch. Orthop. Trauma. Surg.*, 2004, vol. 124, no 2, pp. 134-136.
6. Hardy D.C.R., Delince P.E., Yasik E., Lafontaine M.A. Stress fracture of the hip. An unusual complication of total knee arthroplasty. *Clin. Orthop.*, 1992, vol. 281, pp. 140-144.
7. Rawes M.L., Patsalis T., Gregg P.J. Subcapital stress fractures of the hip complicating total knee replacement. *Injury*, 1995, vol. 26, pp. 421-423.
8. Hendel D., Beloosesky Y., Weisbord M. Fracture of the hip after knee arthroplasty – an unusual case with pain in the knee. *Acta Orthop. Scand.*, 2001, vol. 72, pp. 194-195.

УДК 57.052+618.36+618.346

## NITROGEN METABOLISM OF PLACENTA AND AMNIOTIC FLUID IN NORMAL PREGNANCY DEVELOPMENT

© 2015 г.

**I.I. Krukier, A.S. Degtiareva, E.V. Narezhnaya, V.V. Avrutskaia,  
A.A. Nikashina, L.V. Kravchenko, O.I. Kukhta**

*Krukier Irina Ivanovna – Doctor of Biological Science, Chief Researcher, Department of Medico-Biological Problems in Obstetrics, Gynecology and Pediatrics, Academy of Biology and Biotechnology SFU, Stachki St., 194/1, Rostov-on-Don, 344090; Rostov Scientific Research Institute of Obstetrics and Pediatrics, Mechnikov St., 43, Rostov-on-Don, 344012, Russia, e-mail: biochem@rniiap.ru*

*Degtyareva Anna Sergeevna – Researcher, Department of Medico-Biological Problems in Obstetrics, Gynecology and Pediatrics, Rostov Scientific Research Institute of Obstetrics and Pediatrics, Mechnikov St., 43, Rostov-on-Don, 344012, Russia, e-mail: biochem@rniiap.ru*

*Narezhnaya Elena Vasilievna – Candidate of Chemical Science, Associate Professor, Faculty of Chemistry, Southern Federal University, R. Zorge St., 7, Rostov-on-Don, 344090, Russia, e-mail: evn@sfedu.ru*

*Avrutskaia Valeriya Victorovna – Doctor of Medical Science, Professor, Head of Polyclinic Department, Rostov Scientific Research Institute of Obstetrics and Pediatrics, Mechnikov St., 43, Rostov-on-Don, 344012, Russia, e-mail: biochem@rniiap.ru*

*Nikashina Anastasiya Aleksandrovna – Junior Researcher, Department of Medico-Biological Problems in Obstetrics, Gynecology and Pediatrics, Rostov Scientific Research Institute of Obstetrics and Pediatrics, Mechnikov St., 43, Rostov-on-Don, 344012, Russia, e-mail: biochem@rniiap.ru*

*Kravchenko Larisa Vakhtangovna – Doctor of Medical Science, Leading Researcher, Department of Pediatrics, Rostov Scientific Research Institute of Obstetrics and Pediatrics, Mechnikov St., 43, Rostov-on-Don, 344012, Russia, e-mail: biochem@rniiap.ru*

*Kukhta Olga Ivanovna – Junior Researcher, Obstetrician Pediatric, Department of Newborn, Rostov Scientific Research Institute of Obstetrics and Pediatrics, Mechnikov St., 43, Rostov-on-Don, 344012, Russia, e-mail: biochem@rniiap.ru*

*During normal fetal development are significant changes in the amino acid composition of the placenta and amniotic fluid. In placenta as organ development, the level of arginine, proline and glutamate reduced, and citrulline – increases. Production of arginine in the amniotic fluid increased by 2 times up to 20–23 weeks of pregnancy, and the highest level of proline and citrulline in the amniotic fluid is observed to the 15th week. The development of placenta, the level of all investigated amino acids has increased. Based on these data, we can conclude that by regulation the supply of nutrients to the fetus and fetal growth, placenta thus plays a central role in the «prenatal programming».*

**Keywords:** placenta, amniotic fluid, amino acids, physiological pregnancy, capillary electrophoresis.

### References

1. Pogorelova T.N., Linde V.A., Krukier I.I., Gun'ko V.O., Drukker N.A. *Molekulyarnye mekhanizmy regulyatsii metabolicheskikh protsessov v platsente pri fiziologicheski protokayushchei i oslozhnennoi beremennosti* [Molecular mechanisms of regulation of metabolic processes in the placenta at physiologically proceeding and complicated pregnancy]. Saint Petersburg, 2012, 304 p.
2. Tsitsiou E., Sibley C.P., D'Souza S.W., Catanescu O., Jacobsen D.W., Glazier J.D. Homocysteine is transported by the microvillous plasma membrane of human placenta. *J. Inherit. Metab. Dis.*, 2011, vol. 34, pp. 57-65.
3. Orlov V.I., Pogorelova T.N., Krukier I.I., Sagamonova K.Yu., Drukker N.A. *Okoloplodnye vody. Khimicheskii sostav i*

*fiziologicheskie funktsii* [Amniotic fluid. The chemical composition and physiological functions]. Rostov-on-Don, 2009, 224 p.

4. Dmitrienko N.P., Kishko T.O., Shandarenko S.G. Arginin: biologicheskoe deistvie, vliyanie na sintez oksida azota [Arginine: biological effects, effects on nitric oxide synthesis]. *Ukrainskii khimioterapevticheskii zhurnal*, 2008, no 1, pp. 137-140.

5. Khlybova S.V., Tsirkin V.I., Dvoryanskii S.A., Ezhov A.V., Roman V.V. Gipoargininemiya – etiologicheskii faktor khronicheskoi platsentarnoi nedostatochnosti [Gipoargininemia - etiologic agent of chronic placental insufficiency]. *Voprosy ginekologii, akusherstva i perinatologii*, 2007, vol. 6, no 3, pp. 18-22.

6. Battaglia F.C. Glutamine and Glutamate Exchange between the Fetal Liver and the Placenta. *J. of Nutrition*, 2000, vol. 130, no. 4, pp. 974S-977S.

7. Galan H.L., Marconi A.M., Paolini C.L., Cheung A., Battaglia F.C. The transplacental transport of essential amino

acids in uncomplicated human pregnancies. *Am. J. of Obstet. Gynecol.*, 2009, vol. 200, pp. E1-E7.

8. Cleal J.K., Lewis R.M. The mechanisms and regulation of placental amino acid transport to the human foetus. *J. Neuroendocrinol.*, 2008, no 20(4), pp. 419-426.

9. Pogorelova T.N., Gun'ko V.O., Linde V.A. Transplatsentarnyi perekhod aminokislot i ego vliyanie na «vnutriutrobnoe programmirovaniye» postnatal'noi patologii [Transplacental transfer of amino acids and its effect on the "prenatal programming" postnatal pathology]. *Voprosy ginekologii, akusherstva i perinatologii*, 2013, vol. 12, no 5, pp. 46-52.

10. Van Winkle L.J. Amino acid transport regulation and early embryo development. *Biol. Reprod.*, 2001, vol. 64, no 1, pp. 1-12.

11. Netebenko O.K. Metabolicheskoe programmirovaniye v antenatal'nom periode [Metabolic programming in the antenatal period]. *Voprosy ginekologii, akusherstva i perinatologii*, 2012, vol. 11, no 6, pp. 58-64.

Поступила в редакцию

30 января 2015 г.

УДК 618.346

## METABOLIC STATUS OF PATIENTS WITH HYPOESTROGENIC ANOVULATION ON THE LONG-TERM HORMONE REPLACEMENT THERAPY

© 2015 г. N.B. Chagai, E.G. Bakulina

*Chagai Nataliya Borisovna – Doctor of Medical Science, Professor, Department of Endocrinology, Pediatric Endocrinology, Diabetology, Stavropol State Medical University, Mir St., 310, Stavropol, 355017, Russia, e-mail: chagay2006@rambler.ru*

*Bakulina Elena Gennadievna – Candidate of Medical Science, Head of the Department, Centre for Family Health and Reproduction of the Stavropol Regional Clinical Consultative and Diagnostic Center, Lenin St., 304, Stavropol, 355017, Russia.*

*Assess the influence of estrogen replacement therapy and long-term combined hormone replacement therapy per os on the metabolism of fats and carbohydrates in patients with hypergonadotrophic hypogonadism and premature ovarian failure.*

**Keywords:** *hypogonadotrophic hypogonadism, hypergonadotrophic hypogonadism, hormone replacement therapy, insulin resistance, lipid metabolism.*

### References

1. Chagai N.B. *Metabolicheskii gomeostaz i ego korraktsiya u patsientok s razlichnymi formami anovulyatsii*: avtoref. dis. ... kand. med. nauk [Metabolic homeostasis and its correction in patients with various forms of anovulation]. Moscow, 2003, 24 p.
2. Chagai N.B., Mkrtumyan A.M., Gevorkyan M.A. Sos-toyanie metabolizma uglevodov i zhirov u patsientok s gipoestrogennymi formami anovulyatsii na fone dolgovremennoi zamestitel'noi gormonal'noi terapii [The state of the metabolism of carbohydrates and fats in patients with anovulation gipoestrogenic forms on the background of long-term hormone replacement therapy]. *Problemy reproduktivnoi meditsiny*, 2011, no 3, pp. 10-14.
3. Manukhin I.B., Gevorkyan M.A., Chagai N.B. *Anovulyatsiya i insulinorezistentnost'* [Anovulation and insulin resistance]. Moscow, 2006, 416 p.
4. Available at: <http://www.issam.ch/freetesto.htm> (accessed 10.12.2014).
5. McAuley K.A., Williams S.M., Mann J.I., Walker R.J., Lewis-Barned N.J., Temple L.A., Duncan A.W. Diagnosing Insulin Resistance in the General Population. *Diabetes Care*, 2001, vol. 24, pp. 460-464.
6. Esteghamati A., Ashraf H., Esteghamati A.R., Meysamie A., Khalilzadeh O., Nakhjavani M., Abbasi M. Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance. *Diabetes Res. Clin. Pract.*, 2009, vol. 84(3), pp. 279-287.
7. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome - a new worldwide definition. *Lancet*, 2005, vol. 366(9491), pp. 1059-1062.

8. Ohwada R., Hotta M., Oikawa S., Takano K. Etiology of hypercholesterolemia in patients with anorexia nervosa. *Int. J. Eat Disord.*, 2006, vol. 39(7), pp. 598-601.
9. Zektser V.Yu. *Gipogonadotropnyi gipogonadizm u zhenshchin: patogenez, diagnostika, klinicheskaya kharakteristika: avtoref. dis. ... kand. med. nauk* [Hypogonadotropic hypogonadism in women: pathogenesis, diagnosis, clinical characteristics]. Moscow, 2008, 20 p.
10. Gonzalez C., Alonso A., Grueso N.A., Diaz F., Esteban M.M., Fernandez S., Patterson A.M. Role of 17beta-estradiol administration on insulin sensitivity in the rat: implications for the insulin receptor. *Steroids*, 2002, vol. 67 (13-14), pp. 993-1005.
11. Rontu R., Solakivi T., Teisala K., Lehtimäki T., Punnonen R., Jokela H. Impact of long-term hormone replacement therapy on in vivo and in vitro markers of lipid oxidation. *Free Radic. Res.*, 2004, vol. 38(2), pp. 129-137.
12. Isotton A.L., Wender M.C., Czepielewski M.A. The influence of estrogen and progestogen replacement on growth hormone activity in women with hypopituitarism. *Arq. Bras. Endocrinol. Metabol.*, 2008, vol. 52(5), pp. 901-916.
13. Christiansen J.J., Fisker S., Gravholt C.H., Bennett P., Svestrup B., Andersen M., Feldt-Rasmussen U., Christiansen J.S., Jørgensen J.O. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. *Eur. J. Endocrinol.*, 2005, vol. 152(5), pp. 719-726.
14. Zaidieva Ya.Z. *Zamestitel'naya gormonoterapiya. Farmakologiya i klinicheskoe primenenie* [Hormone replacement therapy. Pharmacology and clinical use]. Moscow, 2001, 50 p.
15. Naaz A., Zakroczymski M., Heine P., Taylor J., Saunders P., Lubahn D., Cooke P.S. Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERalpha): a potential role for estrogen receptor beta (ERbeta). *Horm. Metab. Res.*, 2002, vol. 34(11-12), pp. 758-763.
16. Lamon-Fava S., Herrington D.M., Horvath K.V., Schaefer E.J., Asztalos B.F. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. *Metabolism*, 2010, vol. 59(12), pp. 1794-1800.

Поступила в редакцию

3 февраля 2015 г.

УДК 618.146-006.6:615.382:615.277.3:615.37:612.017.2

## REFLECTIVE DYNAMICS OF GENERAL ADAPTIVE REACTIONS AT PLASMAPHERESIS AND IMMUNOTHERAPY DURING DRUG TREATMENT OF CERVICAL CANCER

© 2015 г. А.А.И. Шихлиарова, А.П. Мен'шенина, Т.И. Моисеенко, Н.Д. Ушакова

*Shikhlyarova Alla Ivanovna – Doctor of Biological Science, Professor, Head of Laboratory of Cancer Biophysics, Rostov Research Oncological Institute, 14 line St., 63, Rostov-on-Don, 344037, Russia, e-mail: onco-sekretar@mail.ru*

*Menshenina Anna Petrovna – Candidate of Medical Science, Leading Researcher, Department of Tumors of the Reproductive System, Rostov Research Oncological Institute, 14 line St., 63, Rostov-on-Don, 344037, Russia, e-mail: rnioi-patology@yandex.ru*

*Moiseenko Tatiana Ivanovna – Doctor of Medical Sciences, Professor, Head of the Department of Gynecological Oncology, Main Researcher, Department of Tumors of the Reproductive System, Rostov Research Oncological Institute, 14 line St., 63, Rostov-on-Don, 344037, Russia, e-mail: onco-sekretar@mail.ru*

*Ushakova Natalia Dmitrievna – Doctor of Medical Sciences, Professor, Physician of the Department of Anesthesiology and Intensive Care, Rostov Research Oncological Institute, 14 line St., 63, Rostov-on-Don, 344037, Russia, e-mail: rnio-i@list.ru*

*We studied the nature of the development of a common adaptive responses in 47 patients with locally advanced cervical cancer T1b2-2bN0-1M0 stages plasmapheresis and chemioimmunotherapy in neoadjuvant mode. It is established that the conduct of plasmapheresis stress inhibits the effect of chemotherapy on the body. This proves the expediency of application of proactive detoxification with locally spread of malignant growth. Holding immunotherapy promotes sustainability of anti-stress reactions.*

**Keywords:** *locally common cancer of the cervix, plasmapheresis, immunotherapy, chemotherapy, adaptive response.*

References

1. Merabishvili V.M., Bakhidze E.V., Laliantsi E.I., Urmancheeva A.F., Krasil'nikov I.A. Rasprostranennost' ginekologicheskogo raka i vyzhivaemost' bol'nykh [The prevalence of gynecological cancer and survival of patients]. *Voprosy onkologii*, 2014, vol. 60, no 3, pp. 288-297.
2. Kosenko I.A., Matylevich O.P., Dudarev V.S., Litvinova T.M., Orekhov V.F., Fomina I.N., Kurchina T.M., Osipova T.V. Effektivnost' kompleksnogo lecheniya mestnorasprostranennogo raka sheiki matki s ispol'zovaniem imioembolizatsii matochnykh arterii [Efficiency of complex treatment of locally advanced cervical cancer using uterine artery imioembolization]. *Onkologiya*, 2012, no 1, pp. 15-19.
3. Zola P., Tripodi E., Zanfagnin V., Balima Poma C., Perotto S., Modafarri P., Marta F., Fuso L. Treatment of early cervical cancer: survival, complication and economical aspects. *Sibirskii onkologicheskii zhurnal*, 2012, no 3 (51), pp. 14-21.
4. Men'shenina A.P., Moiseenko T.I., Ushakova N.D. [Optimization capabilities of preoperative chemotherapy in patients with invasive cervical cancer]. *Zlokachestvennye opukholi: materialy XVIII Rossiiskogo onkologicheskogo kongressa* [Malignant tumors: Proceedings of XVIII Russian Cancer Congress]. Moscow, 2014, pp. 30-36.
5. Bondar' G.V., Oleinikov K.N., Komendant V.V., Lisovskaya N.Yu. Patogeneticheskie obosnovanie i metodicheskie aspekty lechebnogo plazmafereza u bol'nykh, poluchayushchikh protivopukholevuyu lekarstvennuyu terapiyu [Pathogenetic substantiation and methodological aspects of therapeutic plasmapheresis in patients receiving anti-tumor drug therapy]. *Novoutvorennaya*, 2007, no 2, pp. 28-38.
6. Bambauer R., Latzo R., Schiel R. Therapeutic plasma exchange and selective plasma separation methods. *Fundamental technologies, pathology and clinical results*, 2013, pp. 395-402.
7. Nerodo G.A., Ushakova N.D., Goroshinskaya I.A., Mkrtychyan E.T., Men'shenina A.P. Primenenie plazmafereza v kompleksnom lechenii rasprostranennogo raka yaichnikov III-IV stadii [The use of plasmapheresis in the complex treatment of advanced ovarian cancer stage III-IV]. *Izvestiya vuzov. Severo-Kavkazskii region. Estestvennye nauki*, 2014, no 1, pp. 98-102.
8. Ushakova N.D., Nerodo G.A., Goroshinskaya I.A., Zlatnik E.Yu., Mkrtychyan E.T., Men'shenina A.P. Otsenka effektivnosti plazmafereza v lechenii bol'nykh rakom yaichnikov [Evaluating the effectiveness of plasmapheresis in the treatment of patients with ovarian cancer]. *Rossiiskii meditsinskii zhurnal*, 2014, no 3, pp. 21-26.
9. Kovchur P.I., Bakhidze E.V., Volkova T.O. Vliyanie immunomoduliruyushchei terapii na pokazateli kletochnogo immuniteta i aktivnost' apoptoza limfotsitov perifericheskoi krovi u bol'nykh s preinvazivnym i mikroinvazivnym rakom sheiki matki [Influence of immunomodulatory therapy on cellular immunity and activity of apoptosis of peripheral blood lymphocytes in patients with preinvasive and microinvasive cervical cancer]. *Molekulyarnaya diagnostika*, 2014, vol. 2, pp. 202-203.
10. Garkavi L.Kh., Kvakina E.B., Kuzmenko T.S., Shikhlyarova A.I. *Antistressornye reaktsii i aktivatsionnaya terapiya. Reaktsiya aktivatsii kak put' k zdorov'yu cherez protsessy samoregulyatsii* [Antistress reactions and activation therapy. Activation reaction as a way to health through the processes of self-regulation]. Ekaterinburg, 2002, 196 p.
11. Shikhlyarova A.I., Maksimov G.K. Novyi integral'nyi pokazatel' sostoyaniya adaptivnykh protsessov pri provedenii khirurgicheskogo, luchevogo i lekarstvennogo lecheniya raka s ispol'zovaniem autosred organizma [New integral indicator of adaptive processes during surgery, radiotherapy and drug treatment of cancer using autologous environment of the organism]. *Aktual'nye voprosy teoreticheskoi, eksperimental'noi i klinicheskoi onkologii*. Moscow, 2006, pp. 407-416.